FDA actions
TODAY'S HEADLINES
FDA approved Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers. Read more |
ADVERTISEMENT
Solving drug alert challenges to improve patient safety- Free, on-demand webinar.
 Learn More |
|
Patients with Duchenne muscular dystrophy will have a clearer path to treatment with the accelerated approval of eteplirsen (Exondys 51) injection. Read more
|
CONTINUING PHARMACY EDUCATION
This month's CE activity, "The role of the community pharmacy team in assisting patients receiving oral anticancer medications," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians about oral anticancer medications.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More
|
EDITOR'S PICK
PCSK9 inhibitors such as alirocumab (Praluent) and evolocumab (Repatha) are priced too high to benefit the US healthcare system, according to a new study. Find out why
|
|
|
